What CAN’T It Do?
Just yesterday we shared research that shows Adenosine Monophosphate is beneficial for activating the molecular pathway responsible for energy management: AMPK. Well the good news just keeps rolling in.
To further test the metabolic impact of supplemental AMP, researchers introduced AMP to a group of rats fed a high-fat diet. They found that the groups receiving regular doses of AMP had significant reductions in blood pressure, LDL Cholesterol (bad cholesterol), plasma glucose and insulin levels compared to placebo. Furthermore, levels of urinary 8-OHd, a well-established indicator of oxidative stress, were nearly halved in the AMP groups compared to placebo.
The researchers used rats known as SHRSP (spontaneously hypertensive stroke-prone) because they are known to exhibit spontaneous hypertension, hyperlipidaemia and insulin resistance. The efficacy of AMP in treating these biologically fragile specimens gives promise to the use of AMP as an effective therapy for similarly compromised human patients, such as those suffering from one or more of the following conditions: Obesity, Hypertension, Insulin Resistance/Pre-diabetes, etc.